{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', 'Appendix 15: Columbia-Suicide Severity Rating Scale - Since Last Visit (Continued)', 'SUICIDAL BEHAVIOR', 'Since Last', '(Check all that apply, so long as these are separate events; must ask about all types)', 'Visit', 'Actual Attempt:', 'A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as method to kill oneself Intent', 'Yes', 'No', 'does not have to be 100% If there is any intent/desire to die associated with the act, then it can be considered an actual suicide attempt. There does', 'not', 'have to be any injury or harm, just the potential for injury or harm If person pulls trigger while gun is in mouth but gun is broken so no injury results,', 'this is considered an attempt.', 'Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumstances. For example, a highly', 'lethal act that is clearly not an accident 50 no other intent but suicide can be inferred (e.g., gunshot to head, jumping from window of a high floor/story).', 'Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred', 'Have you made a suicide attempt?', 'Have you done anything to harm yourself?', 'Have you done anything dangerous where you could have died?', 'Total of', 'What did you do?', 'Attempts', 'Did you', 'as a way to end your life?', 'Did you want to die (even a little) when you', '?', 'Were you trying to end your life when you', '?', 'Or did you think it was possible you could have died from', '?', 'Or', 'did you do it purely for other reasons/without ANY intention of killing yourself (like to relieve stress, feel better, get', 'sympathy, or get something else to happen)? (Self-Injurious Behavior without suicidal intent)', 'If yes, describe:', 'Yes', 'No', 'Has subject engaged in Non-Suicidal Self-Injurious Behavior?', 'Interrupted Attempt:', 'South', 'When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not for that, actual attempt would have', 'Yes', 'No', 'occurred).', 'Overdose: Person has pills in hand but is stopped from ingesting. Once they ingest any pills, this becomes an attempt rather than an interrupted attempt', 'Shooting Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger. Once they pull the trigger,', 'even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has noose around', 'neck but has not yet started to hang is stopped from doing so.', 'Total of', 'Has there been a time when you started to do something to end your life but someone or something stopped you before you', 'interrupted', 'actually did anything?', 'If fyes, describe:', 'Aborted Attempt:', 'Yes', 'No', 'When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any self-destructive behavior.', 'Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by something else.', 'Has there been a time when you started to do something to (try to end your life but you stopped yourself before you', 'actually did anything?', 'Total of', 'If Tyes, describe:', 'your', 'aborted', 'Preparatory Acts or Behavior:', 'Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought, such as assembling a', 'Yes', 'No', 'specific method (e.g., buying pills, purchasing a gun) or \"preparing for one\\'s death by suicide (e.g., giving things away, writing a suicide note).', 'Have you taken any steps towards making suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun,', 'giving valuables away or writing a suicide note)?', 'If yes, describe:', 'Suicidal Behavior:', 'Yes', 'No', 'Suicidal behavior was present during the assessment period?', 'Suicide:', 'Yes No', 'Answer for Actual Attempts Only', 'Most Lethal', 'Attempt', 'Date:', 'Actual Lethality/Medical Damage:', 'Enter Code', '0. No physical damage or very minor physical damage (e.g., surface scratches).', '1. Minor physical damage (eg., lethargic speech; first-degree burns; mild bleeding; sprains).', '2.', 'Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree burns; bleeding of major vessel).', '3. Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with reflexes intact; third-degree burns', 'less than 20% of body; extensive blood loss but can recover; major fractures).', '4. Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflexes; third-degree burns over 20% of body;', 'extensive blood loss with unstable vital signs; major damage to a vital area).', '5. Death', 'Potential Lethality: Only Answer if Actual Lethality=0', 'Enter Code', 'Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had potential for very serious', 'lethality. put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on train tracks with oncoming train but pulled away', 'before run over).', '0 = Behavior not likely to result in injury', '1 = Behavior likely to result in injury but not likely to cause death', '2 = Behavior likely to result in death despite available medical care', 'o 2008 Research Foundation for Mental Hygione, Inc.', 'C-SSRS-Since Last Visit (Version 1/14/09)', 'Page of 2', 'Page 98 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.16.', 'Appendix 16: Statistical Considerations', '10.16.1. Additional Details on Sample Size Determination', 'The power calculations were based on the longitudinal change from baseline in MG-ADL total', 'score observed in REGAIN (Study ECU-MG-301). The treatment effect (difference between', 'the eculizumab and the placebo arms in mean change (95% CI) from baseline to Week 6 for', 'MG-ADL) was estimated to be - -1.9 (-3.27, -0.55) and the estimated common standard', 'deviation was 3.7. Based on these parameter estimates and the assumption that ALXN1210-', 'MG-306 study will provide similar results, a total of N = 160 patients is required to ensure at', 'least 90% power to reject the null hypothesis of no treatment effect for MG-ADL at the', 'Type I error rate = 5% (2-sided) based on a t-statistic for two independent samples. A', 'simulation-based approach was also adopted to independently verify the sample size calculation', 'in which a large number of virtual datasets were generated with a total of 160 patients', '(equally distributed between two arms) each having a longitudinal profile of change in MG-', 'ADL and baseline MG-ADL score generated according to the treatment-specific variance-', 'covariance structure obtained from REGAIN database. The empirical power was calculated', 'by the proportion of times these virtual trials rejected the null hypothesis based on the', 'MMRM model described above.', '10.16.2. Additional Details on Sensitivity Analysis for Primary Endpoint', 'To assess the credibility of the primary analysis, the following sensitivity analyses are planned,', 'based on assumptions that are unfavorable enough to the ravulizumab group to constitute a', 'convincing stress test of the primary analysis.', '10.16.2.1. Placebo-based Sensitivity Analysis', 'The placebo-based sensitivity analysis will consider the MNAR mechanism for the missing data,', 'where it will be assumed that patients who discontinue early from the ravulizumab group will', 'follow the trajectory of outcomes similar to the one in the placebo group after discontinuation of', 'ravulizumab, taking into account observed values prior to discontinuation (Little, 1996);', '(Ratitch, 2013). Patients discontinuing early from placebo will be assumed to have unobserved', 'outcomes similar to placebo patients who remain on their randomized treatment. The assumption', 'that the efficacy profiles of dropouts after discontinuation of ravulizumab are similar to those of', 'patients in the placebo group provides an estimand of efficacy attributable to patients in the', 'ravulizumab group if received through the time point of interest, while limiting efficacy after', 'early discontinuation to that of the placebo group.', '10.16.2.2. Tipping Point Sensitivity Analysis', 'An additional sensitivity analysis will be performed based on the delta-adjusted stress testing', 'method (tipping point analysis). This approach assumes that patients who discontinue from the', 'active treatment experience worsening defined by a prespecified adjustment (delta) in the', 'primary efficacy endpoint compared with the observed efficacy score of patients that continue', \"the study to next visit (O'Kelley, 2014). Since a negative change in QMG total score indicates\", 'improvement, the prespecified value of delta will be a non-negative fixed quantity. For each', 'value of delta, the treatment effect will be determined and the value of delta for which the', 'Page 99 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}